These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 26858331

  • 1. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR.
    J Clin Oncol; 2016 Apr 01; 34(10):1079-86. PubMed ID: 26858331
    [Abstract] [Full Text] [Related]

  • 2. Molecular Staging of Sentinel Lymph Nodes Identifies Melanoma Patients at Increased Risk of Nodal Recurrence.
    Kimbrough CW, Egger ME, McMasters KM, Stromberg AJ, Martin RC, Philips P, Scoggins CR.
    J Am Coll Surg; 2016 Apr 01; 222(4):357-63. PubMed ID: 26875070
    [Abstract] [Full Text] [Related]

  • 3. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR.
    Ann Surg; 2010 Sep 01; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [Abstract] [Full Text] [Related]

  • 4. The Sunbelt Melanoma Trial.
    Egger ME, Scoggins CR, McMasters KM.
    Ann Surg Oncol; 2020 Jan 01; 27(1):28-34. PubMed ID: 31529312
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C.
    J Clin Oncol; 2010 Feb 10; 28(5):841-6. PubMed ID: 20048184
    [Abstract] [Full Text] [Related]

  • 6. Lessons learned from the Sunbelt Melanoma Trial.
    McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, Sussman JJ, Gershenwald JE, Ross MI, Sunbelt Melanoma Trial.
    J Surg Oncol; 2004 Jul 01; 86(4):212-23. PubMed ID: 15221928
    [Abstract] [Full Text] [Related]

  • 7. Melanoma Patient-Reported Quality of Life Outcomes Following Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon: Results from the Sunbelt Melanoma Trial.
    Egger ME, Kimbrough CW, Stromberg AJ, Quillo AR, Martin RC, Scoggins CR, McMasters KM.
    Ann Surg Oncol; 2016 Mar 01; 23(3):1019-25. PubMed ID: 26744107
    [Abstract] [Full Text] [Related]

  • 8. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
    Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, Sunderkötter C, Kaatz M, Schatton K, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Verver D, Martus P, Garbe C, German Dermatologic Cooperative Oncology Group.
    J Clin Oncol; 2019 Nov 10; 37(32):3000-3008. PubMed ID: 31557067
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM.
    Recent Results Cancer Res; 2000 Nov 10; 157():178-89. PubMed ID: 10857171
    [Abstract] [Full Text] [Related]

  • 10. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M.
    J Clin Oncol; 2015 Dec 01; 33(34):4077-84. PubMed ID: 26503196
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
    Fujisawa Y, Otsuka F, Japanese Melanoma Study Group.
    Melanoma Res; 2012 Oct 01; 22(5):362-7. PubMed ID: 22713797
    [Abstract] [Full Text] [Related]

  • 13. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma.
    Manca G, Romanini A, Pellegrino D, Borsò E, Rondini M, Orlandini C, Zucchi V, Pasqualetti F, Mariani G.
    J Nucl Med; 2008 Nov 01; 49(11):1769-75. PubMed ID: 18927334
    [Abstract] [Full Text] [Related]

  • 14. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
    Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Davidson BS, Sussman JJ, Edwards MJ, Martin RC, Lewis AM, Stromberg AJ, Conrad AJ, Hagendoorn L, Albrecht J, McMasters KM.
    J Clin Oncol; 2006 Jun 20; 24(18):2849-57. PubMed ID: 16782924
    [Abstract] [Full Text] [Related]

  • 15. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
    Broman KK, Hughes TM, Dossett LA, Sun J, Carr MJ, Kirichenko DA, Sharma A, Bartlett EK, Nijhuis AA, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma J, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras RM, Teras J, Farrow NE, Beasley GM, Hui JY, Been L, Kruijff S, Boulware D, Sarnaik AA, Sondak VK, Zager JS, International High-Risk Melanoma Consortium.
    J Am Coll Surg; 2021 Apr 20; 232(4):424-431. PubMed ID: 33316427
    [Abstract] [Full Text] [Related]

  • 16. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
    Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, G Coit D.
    Ann Surg Oncol; 2006 Jun 20; 13(6):809-16. PubMed ID: 16604476
    [Abstract] [Full Text] [Related]

  • 17. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
    Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH.
    J Clin Oncol; 2000 Jun 20; 18(12):2444-58. PubMed ID: 10856105
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, Leccia MT, Landthaler M, Garbe C, Sassolas B, Herbst RA, Guillot B, Chene G, Pehamberger H.
    Eur J Cancer; 2013 Jan 20; 49(1):166-74. PubMed ID: 22975216
    [Abstract] [Full Text] [Related]

  • 19. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
    Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS.
    Cancer; 2021 Jul 01; 127(13):2251-2261. PubMed ID: 33826754
    [Abstract] [Full Text] [Related]

  • 20. Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival.
    Woeste MR, McMasters KM, Egger ME.
    J Am Coll Surg; 2021 Apr 01; 232(4):517-524.e1. PubMed ID: 33316426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.